Mark Egly Foundation
  • Why We Exist
    Our Mission
    Our PromiseOur ImpactOur AgendaMark's StoryMark's PatentCurrent Partnerships
    Standard of Care
    What is the SOCChanging the SOCOur Research StrategyKey InitiativesNews
    Alpha1 Antitrypsin
    State of the FieldOur Research StrategyKey Research InitiativesResearch News
  • Understanding Alpha1
    About Alpha1
    What is Alpha1What is Alpha1 Antitrypsin DeficiencySymptomsMedication & TreatmentsRelated ConditionsAge Relevance to Diagnosis
    Alpha1 Journey
    Newly Diagnose ResourcesAlpha1 360Building a Support TeamWork & Financial ConcernsRelationshipsMental & Physical Health
    Education & Inspiration
    Alpha1 and You EventsAsk the MDWebinarsPodcastsBooks & ResourcesAlpha1 Friend Network
  • For Researchers
    Apply for Grants
    What We FundFunding OpportunitiesWorking with UsFunded Studies
  • Take Action
    Donate
    Donate NowMonthly Giving ProgramWays to GiveIn TributeEmployee GivingPlanned Giving
    Advocate
    Contact Your PolicymakersOur Public Policy PrioritiesAdvocacy ResourcesPolicy Updates

Traditional Medications & Treatments for Alpha1 Antitrypsin Deficiency

Augmentation Therapy

Is traditionally a once-a-week infusion of Alpha1 Antitrypsin to raise the level of circulating Alpha1 Antitrypsin in the body.

Currently, there are four companies with FDA Approved medications to raise AAT levels in the body; those medications are:

  • Aralast
  • Glassia
  • Prolastin
  • Zemaira